Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2221-2232

  Clayman, Gary L ^a   El Naggar, Adel K ^a   Lippman, Scott M ^a   Henderson, Ying Cha ^a   Frederick, Mitchell ^a   Merritt, James A ^a   Zumstein, Louis A ^a   Timmons, Therese M ^a   Liu, Ta Jen ^a   Ginsberg, Lawrence ^a   Roth, Jack A ^a   Hong, Waun Ki ^a   Bruso, Patricia ^a   Goepfert, Helmuth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADENOVIRUS; ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GENE THERAPY; GENE TRANSFER; HEAD AND NECK CARCINOMA; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0031750168     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2221     Document Type: Article

References (53)

1. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
2. Day GL, Blot WJ, Shore RE, et al: Second cancers following oral and pharyngeal cancers: Role of tobacco and alcohol. J Natl Cancer Inst 86:131-137, 1994
3. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997
4. Clayman GL, Lippman SM, Laramore GE, et al: Head and neck cancer, in Holland JF, Frei E III, Bast RC, et al (eds): Cancer Medicine (ed 4). Baltimore, MD, Williams & Wilkins, 1997, pp 1645-1710
5. Raybaud-Diogene H, Tetu B, Morency R, et al: p53 overexpression in head and neck squamous cell carcinoma: Review of the literature. Eur J Cancer B Oral Oncol 326:143-149, 1996
6. Ko LJ, Prives C: p53: Puzzle and paradigm. Genes Dev 10:1054-1072, 1996
7. Hansen R, Oren M: p53: From inductive signal to cellular effect. Curr Opin Genet Dev 7:46-51, 1997
8. Berkner KL: Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 6:616-629, 1988
9. Horwitz MS: Adenoviruses, in Fields BN, Knipe DM, Howley PM, et al (eds): Fields Virology (ed 3). Philadelphia, PA, Lippincott-Raven Publishers, 1996, pp 2149-2171
10. Chen P-L, Chen Y, Bookstein R, et al: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1580, 1990
11. Yonish-Rouach E, Resnitzky D, Rotem J, et al: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345-347, 1991
12. Shaw P, Bovey R, Tardy S, et al: Induction of apoptosis of wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4499, 1992
13. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53:4129-4133, 1993
14. Clayman GL, El-Naggar AK, Roth JA, et al: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55:1-6, 1995
15. Hamada K, Alemany R, Zhang W-W, et al: Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 56:3047-3054, 1996
16. Liu TJ, El-Naggar AK, McDonnell TJ, et al: Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55:3117-3122, 1995
17. Noble JR, Willetts KE, Mercer WE, et al: Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp Cell Res 203:297-304, 1992
18. Liu T-J, Zhang W-W, Taylor DL, et al: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54:3662-3667, 1994
19. Nguyen DM, Spitz FR, Yen N, et al: Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112:1372-137, 1996
20. Nielsen LL, Dell J, Maxwell E, et al: Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 4:129-138, 1997
21. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus- mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994
22. Pirollo KP, Hao Z, Rait A, et al: p53-mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 14:1735-1746, 1997
23. Spitz FR, Nguyen D, Skibber JM, et al: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2:1665-1671, 1996
24. Zhang WW, Fang X, Branch CD, et al: Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques 15:868-872, 1993
25. Ajani JA, Welch SR, Raber MN, et al: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147-159, 1990
26. Ausubel FM, Brent R, Kingston RE, et al: Current Protocols in Molecular Biology. New York, NY, John Wiley & Sons, Inc, 1995
27. Graham FL, Smiley J, Russell WC, et al: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-72, 1997
28. Cunningham R, Harris A, Frankton A, et al: Detection of cytomegalovirus using PCR in serum from renal transplant recipients. J Clin Pathol 48:575-577, 1995
29. Lennette EH, Lennette DA, Lennette ET: Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections (ed 7). Washington, DC, American Public Health Association, 1995
30. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981
31. Oren M, Reich NC, Levine AJ: Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol 2:443-449, 1982
32. Schornagel JH, Verweij J, de Mulder PHM, et al: Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol 13:1649-1655, 1995
33. Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 2:985-991, 1996
34. Cusack JC, Spitz FR, Nguyen D, et al: High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther 3:245-249, 1996
35. Van Meir EG, Polverini PJ, Chazin VR, et al: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat Genet 8:171-176, 1994
36. Dameron KM, Volpert OV, Tainsky MA, et al: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994
37. Mukhopadhyay D, Tsiokas L, Sukhatme VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55:6161-6165, 1995
38. Shenk T, Jones N, Colby W, et al: Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells. Cold Spring Harb Symp Qaunt Biol 44:367-375, 1980
39. Hainaut P, Soussi T, Shomer B, et al: Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects. Nucleic Acids Res 25:151-157, 1997
40. Sjogren S, Inganas M, Norberg T, et al: The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182, 1996
41. Oliner JD, Kinzler KW, Meltzer PS, et al: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83, 1992
42. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
43. Crystal R, McElvaney N, Rosenfeld M, et al: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 8:42-51, 1994
44. Zabner J, Ramsey BW, Meeker DP, et al: Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 97:1504-1511, 1996
45. Hierholzer JC: Adenoviruses in the immunocompromised host. Clin Microbiol Rev 5:262-274, 1992
46. Knowles MR, Hohneker KW, Zhou Z, et al: A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New Engl J Med 333:823-831, 1995
47. Yang Y, Nunes FA, Berencsi K, et al: Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407-4411, 1994
48. Dai Y, Schwarz EM, Gu D, et al: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92:1401-1405, 1995
49. Fox J, Brandt C, Wassermann F, et al: The Virus Watch Program: A continuing surveillance of viral infections in metropolitan families. Am J Epidemol 89:25-50, 1969
50. Bramson JL, Hitt M, Gauldie J, et al: Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 4:1069-1076, 1997
51. Huebner RJ, Rowe WP, Chanock RM: Newly recognized respiratory tract viruses. Annu Rev Microbiol 12:49-76, 1958
52. Brennan JA, Mao L, Hruban RH, et al: Molecular assessment of histopathologic staging. New Engl J Med 332:429-435, 1995
53. Boyle JO, Hakim J, Koch W, et al: The incidence of p53 mutation increases with progression of head and neck cancer. Cancer Res 53:4477-4480, 1993